Squarepoint
CODX

Squarepoint’s Co-Diagnostics CODX Stock Holding History

Squarepoint’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,193
Closed -$20.4K – 4565
2025
Q1 		$20.4K Buy
2,193
+1,248
+132% +$23.9K ﹤0.01% 4436
2024
Q4 		$21.3K Buy
+945
New +$29.8K ﹤0.01% 4931
2023
Q2 		– Sell
-353
Closed -$15.7K – 3620
2023
Q1 		$15.7K Buy
+353
New +$28.3K ﹤0.01% 3141
2021
Q3 		– Sell
-739
Closed -$183K – 2980
2021
Q2 		$183K Buy
+739
New +$190K ﹤0.01% 2866
2021
Q1 		– Sell
-829
Closed -$231K – 3181
2020
Q4 		$231K Buy
+829
New +$307K ﹤0.01% 2409

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's CODX Position: Q2 2025 in Review

Squarepoint sold out of Co-Diagnostics (CODX) in Q2 2025, closing a stake of 2,193 shares — an estimated $20.4K sold.

Squarepoint first reported a position in CODX in Q4 2020 and held it in 5 quarters. The position peaked at $231K in Q4 2020. 35 funds tracked by Wall St. Rank hold CODX as of Q2 2025.

  • Squarepoint reported no remaining Co-Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 2,193 Co-Diagnostics shares in Q2 2025, an estimated $20.4K.
  • Squarepoint first reported a position in Co-Diagnostics in Q4 2020 and held it in 5 quarters.
  • Squarepoint's Co-Diagnostics position peaked at $231K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.